Balyasny Asset Management
JAZZ icon

Balyasny Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Balyasny Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$3.69M – 3044
2024
Q4 		$3.69M Buy
30,000
+20,000
+200% +$2.36M 0.01% 1414
2024
Q3 		$1.11M Buy
+10,000
New +$1.1M ﹤0.01% 1922
2024
Q1 		– Sell
-50,000
Closed -$6.15M – 2865
2023
Q4 		$6.15M Buy
+50,000
New +$6.24M 0.01% 1050
2014
Q3 		– Sell
-50,000
Closed -$7.35M – 787
2014
Q2 		$7.35M Buy
+50,000
New +$6.93M 0.08% 294

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Balyasny Asset Management's JAZZ Position: Q1 2026 in Review

Balyasny Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 48,108 shares — an estimated $8.18M sold.

Balyasny Asset Management first reported a position in JAZZ in Q2 2013 and held it in 33 quarters. The position peaked at $57.1M in Q3 2025. 572 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Balyasny Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 48,108 Jazz Pharmaceuticals shares in Q1 2026, an estimated $8.18M.
  • Balyasny Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Balyasny Asset Management's Jazz Pharmaceuticals position peaked at $57.1M in Q3 2025.
  • 572 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.